Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer
Table 5
Resource use of CAPN cases and non-CAPN controls during the 12-month study period.
(A) Main Sample: no diabetes
(B) Diabetes Sample
Cases
Controls
-valuea
Cases
Controls
-valuea
No.
%
No.
%
No.
%
No.
%
454
454
71
71
Resource use rate
Medical
Hospitalizations
231
51%
166
37%
<.0001
48
68%
32
45%
0.0136
ED visits
213
47%
170
37%
0.0037
42
59%
27
38%
0.0222
Outpatient visits
453
100%
447
98%
0.0339
71
100%
70
99%
0.0339
Oncology
288
63%
250
55%
0.0075
43
61%
39
55%
0.5050
Neurology
133
29%
29
6%
<.0001
30
42%
5
7%
<.0001
Primary care
354
78%
345
76%
0.4726
59
83%
60
85%
0.8185
Other physician
444
98%
428
94%
0.0035
71
100%
66
93%
0.0035
Lab/pathology
181
40%
160
35%
0.1540
21
30%
22
31%
0.8694
Other outpatient
400
88%
369
81%
0.0030
68
96%
61
86%
0.0522
Prescription drug use
At least 1 CAPN-related drug
329
72%
256
56%
<.0001
66
93%
46
65%
0.0003
Resource use amount
Mean
(SD)
Mean
(SD)
-valuea
Mean
(SD)
Mean
(SD)
-valuea
Medical
Hospitalizations
5.6
(11.69)
3.2
(7.77)
0.0001
9.1
(14.38)
6.2
(13.44)
0.2195
ED visits
1.1
(2.80)
0.6
(1.28)
0.0022
1.6
(1.98)
0.8
(1.35)
0.0064
Outpatient visits
51.3
(29.57)
39.8
(26.81)
<.0001
56.9
(27.02)
38.5
(25.10)
<.0001
Oncology
12.7
(18.92)
9.2
(15.55)
0.0021
12.6
(16.97)
7.5
(10.62)
0.0322
Neurology
0.6
(1.29)
0.1
(0.51)
<.0001
1.1
(1.87)
0.1
(0.56)
0.0002
Primary care
6.9
(12.65)
5.0
(8.74)
0.0085
7.4
(10.25)
5.7
(5.64)
0.2454
Other physician
22.1
(21.22)
17.2
(18.82)
0.0001
25.9
(20.63)
18.6
(18.82)
0.0217
Lab/pathology
1.1
(2.62)
0.9
(2.49)
0.2127
0.8
(3.59)
1.1
(3.93)
0.6594
Other outpatient
13.6
(16.47)
11.4
(15.97)
0.0349
15.5
(15.37)
11.0
(16.56)
0.0905
CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation; ED, emergency department.
a-values are determined using McNemar tests for proportions and paired -tests for continuous measures.
